NCT03427931

CGM Use in Islet Transplant Recipients

Continuous Glucose Monitoring in Islet Transplant Recipients

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 7 (actual)
• Sponsor: University of Virginia · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A study assessing glucose variability in subjects with Type 1 Diabetes who have had islet transplant.

Detailed description

Subjects who have an Islet Transplantation may have several outcomes including time when insulin is not required followed in some cases by additional insulin for glucose control as patients get further away from transplantation. It is unclear what role automated insulin delivery systems will have in addressing glucose variability in this group of patients who may have some amount of islet function. As a precursor to understanding ways in which automated insulin delivery systems may need to be adapted, we propose to gather data on glucose variability and insulin regimens in individuals who have undergone an islet transplantation.

Conditions

• Islet Transplantation
• Type1 Diabetes Mellitus

Interventions

Type	Name	Description
OTHER	Continuous Glucose Monitor (CGM)	Study subjects will collect Continuous Glucose Monitor data for a minimum of 28 days but may continue for up to 3 months.

Timeline

• Start date: 2018-02-01
• Primary completion: 2019-07-11
• Completion: 2019-07-11
• First posted: 2018-02-09
• Last updated: 2020-08-07
• Results posted: 2020-08-07

Locations

1 site across 1 country: United States